Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) as the first treatment for people with chronic fibrosing interstitial lung diseases…Original Article
FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype
